IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients

Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice

(2012) María Paula Roberti et al.   CANCER BIOLOGY & THERAPY

Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer

(2012) Javier Rodríguez et al.   EUROPEAN JOURNAL OF CANCER

Monoclonal Antibody Therapy of Pancreatic Cancer With Cetuximab

(2012) Eric Luedke et al.   JOURNAL OF IMMUNOTHERAPY

IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR

(2011) M. P. Roberti et al.   BREAST CANCER RESEARCH AND TREATMENT

Modulation of tumor immunity by therapeutic monoclonal antibodies

(2011) Riad Abès et al.   CANCER AND METASTASIS REVIEWS

Human Breast Tumor Cells Induce Self-Tolerance Mechanisms to Avoid NKG2D-Mediated and DNAM-Mediated NK Cell Recognition

(2011) E. Mamessier et al.   CANCER RESEARCH

Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma

(2011) S. Platonova et al.   CANCER RESEARCH

Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients

(2011) N. Azzopardi et al.   CLINICAL CANCER RESEARCH

Role of Common-Gamma Chain Cytokines in NK Cell Development and Function: Perspectives for Immunotherapy

(2011) Raffaella Meazza et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity

(2011) Emilie Mamessier et al.   JOURNAL OF CLINICAL INVESTIGATION

Triple-Negative Breast Cancers: Unique Clinical Presentations and Outcomes

(2010) Julie A. Y. Billar et al.   ANNALS OF SURGICAL ONCOLOGY

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer

(2010) Alfonso Sánchez-Muñoz et al.   BMC CANCER

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer

(2010) Melissa A. Geller et al.   CYTOTHERAPY

Deconstructing the molecular portraits of breast cancer

(2010) Aleix Prat et al.   Molecular Oncology

Triple-negative breast cancer: disease entity or title of convenience?

(2010) Lisa Carey et al.   Nature Reviews Clinical Oncology

NK Cell Terminal Differentiation: Correlated Stepwise Decrease of NKG2A and Acquisition of KIRs

(2010) Vivien Béziat et al.   PLoS One

Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells

(2009) M. Carlsten et al.   JOURNAL OF IMMUNOLOGY

Up-regulation of NK Cell Activating Receptors Following Allogeneic Hematopoietic Stem Cell Transplantation under a Lymphodepleting Reduced Intensity Regimen is Associated with Elevated IL-15 Levels

(2008) Michael Boyiadzis et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity

(2008) Giuseppe Viale et al.   BREAST CANCER RESEARCH AND TREATMENT

Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56brightCD16− cells and display an impaired capability to kill tumor cells

(2008) Paolo Carrega et al.   CANCER

Potential Role of NK Cells in the Induction of Immune Responses: Implications for NK Cell–Based Immunotherapy for Cancers and Viral Infections

(2008) Hiroshi Terunuma et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Functions of natural killer cells

(2008) Eric Vivier et al.   NATURE IMMUNOLOGY

Stromal gene expression predicts clinical outcome in breast cancer

(2008) Greg Finak et al.   NATURE MEDICINE

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE